ArticleJournal of neuroinflammation2019
Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
Article in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Partitioned glioma heritability shows subtype-specific enrichment in immune cells.Neuro-oncology · 2021Pooled it
- Glioma tumor microenvironment and immunotherapy: past, present, and future.Biomarker research · 2025Review
- HLA-F regulates the proliferation of trophoblast via PKM2-dependent glycolysis in the pathogenesis of preeclampsia.Molecular medicine (Cambridge, Mass.) · 2025Article
- The Mechanism of Action of Exosomes Derived from Glioblastoma Cells.Current medicinal chemistry · 2025Review
- Machine learning-based identification of a cell death-related signature associated with prognosis and immune infiltration in glioma.Journal of cellular and molecular medicine · 2024Article
- Diversity in the HLA-I Recognition of HLA-F Monoclonal Antibodies: HLA-F or HLA-Ib Monospecific, HLA-E or HLA-G Bispecific Antibodies with or without HLA-Ia Reactivity.Antibodies (Basel, Switzerland) · 2024Article
- Harnessing natural killer cell effector function against cancer.Immunotherapy advances · 2024Review
- IFN-γ Triggered IFITM2 Expression to Induce Malignant Phenotype in Elderly GBM.Journal of molecular neuroscience : MN · 2023Article
- The Crosstalk between the EGFR and IFN-γ Pathways and Synergistic Roles in Survival Prediction and Immune Escape in Gliomas.Brain sciences · 2023Article
- Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma.Cancer science · 2023Article
- Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management.International journal of molecular sciences · 2022Review
- Elevated TAF12 Expression Predicts Poor Prognosis in Glioma Patients: Evidence from Bioinformatic and Immunohistochemical Analyses.Biomolecules · 2022Article
- Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma.Translational cancer research · 2022Article
- Article
- Correlation of AIF-1 Expression with Immune and Clinical Features in 1270 Glioma Samples.Journal of molecular neuroscience : MN · 2022Article
- Identification of an ACK1/TNK2-based prognostic signature for colon cancer to predict survival and inflammatory landscapes.BMC cancer · 2022Article
- Construction and validation of an angiogenesis-related gene expression signature associated with clinical outcome and tumor immune microenvironment in glioma.Frontiers in genetics · 2022Article
- SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma.Frontiers in genetics · 2022Article
- Upregulation of miR-144-3p expression attenuates glioma cell viability and invasion by targeting BCL6.Experimental and therapeutic medicine · 2021Article
- Differential and Prognostic Significance of HOXB7 in Gliomas.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHuman gliomas are highly fatal tumors with a significant feature of immune suppression. The association of the immune system in gliomas is gradually revealed, and immunotherapy is expected to improve the survival of glioma patients. In-depth understanding of the immune microenvironment of gliomas and their associated immunotherapy was increased exponentially in recent years. Gliomas provide clinical targets for immunotherapy during the search of key regulators of immune response. Our study focused on the human leukocyte antigen (HLA) system that is responsible for regulating the immune system, and discovered the relationship between HLA-F expression and clinical prognosis in gliomas.
methodsA total of 593 patients with gliomas were included in our research. Of these, 325 patients were from the Chinese Glioma Genome Atlas (CGGA) and 268 were from the GSE 16011 set. Kaplan-Meier (KM) analysis was performed to explore the prognostic value of HLA-F. t test analysis was used to find the distribution difference in various groups. R language packages are used for other statistical computations and figure drawing.
resultsHLA-F was negatively correlated with overall survival (OS) in all grades of glioma and glioblastoma (GBM). Moreover, HLA-F was enriched in GBM and isocitrate dehydrogenase 1 wild-type (IDH1 wt) group and considered HLA-F as a mesenchymal subtype marker. Pearson correlation test showed that HLA-F was correlated with other HLA-I molecules.
conclusionHLA-F expression was positively correlated with malignant phenotype and negatively correlated with OS, indicating that HLA-F could predict the immune state of gliomas and might be a clinical target of glioma immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.